| Biomarker ID | 1899 |
| PMID | 30611450 |
| Year | 2019 |
| Biomarker | MYC |
| Biomarker Basis | Expression Based |
| Biomolecule | DNA (Copy Number variations) |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Agressive PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Signal transduction, Gene expression, Interleukin-2 signaling pathway, Disease, Binding of RNA by insulin-like growth factor 2 mRNA binding proteins (IGF2BPs/IMPs/VICKZs) |
| Experiment | Gleason Grade 4 in Gleason Score 7 |
| Type of Biomarker | Prognostic |
| Cohort | 124 patients, were chosen GS6 (n=41), large volume GS6 (n=26), GS7 (n=28), and GS8 and higher (n=29). |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.90 (95% CI: 0.82-0.97) |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | fluorescence in situ hybridization (FISH) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |